Evidence map›Paper›PMID 30292090›Full record

ArticleNeurobiology of aging2018

CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia.

Wendy E Heywood, Jenny Hallqvist, Amanda J Heslegrave, Henrik Zetterberg, Chiara Fenoglio, Elio Scarpini, Jonathan D Rohrer, Daniela Galimberti, Kevin Mills

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Cerebrospinal-fluid Orexin-A levels in different neurocognitive disorders: a comparison study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. TheNeural regeneration research · 2021
    Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Wendy E HeywoodCentre for Translational Omics, Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK.
Jenny HallqvistCentre for Translational Omics, Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK.
Amanda J HeslegraveDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Salhgrenska Academy at the University of Gothenburg, Sweden.
Chiara FenoglioNeurodegenerative Disease Unit, University of Milan, Centro Dino Ferrari, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.
Elio ScarpiniNeurodegenerative Disease Unit, University of Milan, Centro Dino Ferrari, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.
Jonathan D RohrerDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Daniela GalimbertiNeurodegenerative Disease Unit, University of Milan, Centro Dino Ferrari, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.
Kevin MillsCentre for Translational Omics, Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK. Electronic address: kevin.mills@ucl.ac.uk.
Great Ormond Street Hospital · GBUniversity of Milan · ITNational Hospital for Neurology and Neurosurgery · GBSahlgrenska University Hospital · SEUK Dementia Research Institute · GB

Funding

Medical Research Council MR/J009482/1Medical Research Council MR/M008525/1Medical Research Council MR/M023664/1Medical Research Council MR/N028678/1
6 · The paper itself

Abstract

There is an unmet need for markers that can stratify different forms and subtypes of dementia. Because of similarities in clinical presentation, it can be difficult to distinguish between Alzheimer's disease (AD) and frontotemporal dementia (FTD). Using a multiplex targeted proteomic LC-MS/MS platform, we aimed to identify cerebrospinal fluid proteins differentially expressed between patients with AD and FTD. Furthermore analysis of 2 confirmed FTD genetic subtypes carrying progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72) mutations was performed to give an insight into the differing pathologies of these forms of FTD. Patients with AD (n = 13) demonstrated a significant (p < 0.007) 1.24-fold increase in pro-orexin compared to FTD (n = 32). Amyloid beta-38 levels in patients with AD were unaltered but demonstrated a >2-fold reduction (p < 0.0001) in the FTD group compared to controls and a similar 1.83-fold reduction compared to the AD group (p < 0.001). Soluble TREM2 was elevated in both dementia groups but did not show any difference between AD and FTD. A further analysis comparing FTD subgroups revealed slightly lower levels of proteins apolipoprotein E, CD166, osteopontin, transthyretin, and cystatin C in the GRN group (n = 9) compared to the C9orf72 group (n = 7). These proteins imply GRN FTD elicits an altered inflammatory response to C9orf72 FTD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesC9orf72 ProteinFemaleFrontotemporal DementiaHigh-Throughput Screening AssaysHumansMaleMiddle AgedOrexinsPeptide FragmentsProgranulinsProteomicsTandem Mass SpectrometryAmyloid beta-Peptidesamyloid beta-protein (1-38)C9orf72 ProteinC9orf72 protein, humanGRN protein, humanOrexinsPeptide FragmentsProgranulinsAlzheimer's diseaseAmyloid β-38C9orf72Frontotemporal dementiaOrexinProgranulin

Identifiers

PMID30292090
PMCPMC6221294
OpenAlexW2888717677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.